There are currently 1250 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Diaphragmatic Hernia Research & Exploration, Advancing Molecular Science
NCT00950118
Recruiting
The goal of this study is to identify genes that convey susceptibility to congenital diaphragmatic hernia in humans. The identification of such genes, and examination of their structure and function, will enable a delineation of molecular pathogenesis and, ultimately, prevention or treatment of congenital diaphragmatic hernia. There are many different possible modes of inheritance for congenital anomalies, including autosomal dominant, autosomal recessive, and multifactorial. Multi-factorial inh... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/30/2025
Locations: Monroe Carrell Jr Children's Hospital at Vanderbilt, Nashville, Tennessee
Conditions: Congenital Diaphragmatic Hernia
Register for Updates
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML
NCT04256317
Recruiting
Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose Expansion Stage (Stage B). Phase 2 is a randomized, open-label, crossover study to compare oral ASTX030 to subcutaneous (SC) azacitidine. Phase 3 is a randomized open-label crossover study comparing the fi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Myelodysplastic Syndrome/Neoplasm, Chronic Myelomonocytic Leukemia
Register for Updates
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
NCT04374877
Recruiting
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Vanderbilt University Medical Center (VUMC), Nashville, Tennessee
Conditions: Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
Register for Updates
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT05563220
Recruiting
This is a multicenter, Phase 1b/2 trial. The phase 1b part of the trial aims to determine the RP2D of elacestrant when administered in combination with alpelisib, everolimus, palbociclib, abemaciclib, and ribociclib. The Phase 2 part of the trial will evaluate the efficacy and safety of the various combinations in patients with ER+/HER2- advanced/metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Sarah Cannon Research Institute / Tennessee Oncology, Nashville, Tennessee
Conditions: Breast Cancer, Metastatic Breast Cancer
Register for Updates
Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
NCT06414460
Recruiting
The study has consists of two parts, a dose escalation part (Part 1) and a dose selection optimization part (Part 2). The primary objectives of this study are to evaluate the safety and tolerability of ISM3412 in participants with locally advanced/metastatic solid tumors, and to determine the RP2D of ISM3412.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Locally Advanced/Metastatic Solid Tumors
Register for Updates
A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia
NCT06525636
Recruiting
A first-in-human study of KK8123 in adults with X-linked hypophosphatemia.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/30/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: X-linked Hypophosphatemia
Register for Updates
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
NCT04503265
Recruiting
ATLAS-101 is a Phase I/II clinical trial of AMXI-5001 in adult participants with advanced malignancies who have previously failed other therapies. The study has two phases. The purpose of Phase I (Dose Escalation) is to confirm the appropriate treatment dose and Phase II (Dose Expansion) is to characterize the safety and efficacy of AMXI-5001.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Advanced Malignant Neoplasm, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency, Prostate Cancer, Pancreatic Cancer
Register for Updates
Pounce™ Thrombectomy System Retrospective Registry
NCT05868161
Recruiting
The PROWL registry is an open-label retrospective, multi-center, US study of the Surmodics™ Pounce™ Thrombectomy System for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Peripheral Arterial Disease, Acute Limb Ischemia
Register for Updates
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
NCT06056830
Recruiting
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Urology Associates of Nashville, Nashville, Tennessee
Conditions: Prostate Cancer, Prostatic Neoplasms
Register for Updates
Addressing Under-treatment and Health Equity in AS and MR Using an Integrated EHR Platform
NCT06099665
Recruiting
This multi-center, prospective, cluster-randomized controlled trial will evaluate Tempus Next automated notifications as an intervention to support identification and evaluation of patients possibly indicated for Valve Intervention (VI). This study will evaluate the impact of Tempus Next's automated notifications on: (1) Transcatheter or surgical procedure for AS or MR; and (2) Clinic visit with at least one member of the Multidisciplinary Heart Team (including time to evaluation) for patients w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Vanderbilt, Nashville, Tennessee
Conditions: Aortic Valve Stenosis, Mitral Regurgitation
Register for Updates
Global Paradise System US Post Approval Study
NCT06297291
Recruiting
The objective of the Global Paradise® System US Post Approval Study (US GPS) is to evaluate the real-world use of the Paradise Ultrasound Renal Denervation System indicated for patients who are unable to lower their blood pressure with lifestyle changes and medication. This system is comprised of a catheter, cable, balloon, and generator and has received FDA approval in the United States. Information collected in this study will be analyzed to better understand the long-term safety and effective... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Ascension Saint Thomas, Nashville, Tennessee
Conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases
Register for Updates
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
NCT06545942
Recruiting
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-313 administered orally as a single agent or combination therapy in patients with homologous recombinant deficient solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Investigative Site #102, Nashville, Tennessee
Conditions: Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency
Register for Updates